drugset / Trial / NCT03593447
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
Phase 2
Completed
133 enrolled
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.
Timeline
- Start
- 2018-03-15
- Primary completion
- 2019-04-23
- Completion
- 2020-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Furaprevir | Small molecule | 200 mg | — |
| Subject | Furaprevir | Small molecule | 400 mg | — |
| Subject | Ribavirin | Small molecule | 1000 mg | — |
| Subject | Ribavirin | Small molecule | 1200 mg | — |
| Subject | Yimitasvir | Small molecule | 100 mg | — |
| Subject | Yimitasvir | Small molecule | 200 mg | — |